Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

Core Viewpoint - Zevra Therapeutics, Inc. has announced a public offering of 9,230,770 shares of common stock at a price of $6.50 per share, aiming for total gross proceeds of approximately $60 million before expenses [1]. Group 1: Offering Details - The offering is expected to close on August 12, 2024, subject to customary closing conditions [1]. - Zevra has granted underwriters a 30-day option to purchase an additional 1,384,615 shares at the public offering price [1]. - Cantor and William Blair are acting as joint book-running managers, with Citizens JMP and H.C. Wainwright & Co. as co-managers [2]. Group 2: Regulatory Information - The offering is made pursuant to a registration statement on Form S-3, which was filed with the SEC on June 4, 2024, and became effective on June 13, 2024 [3]. Group 3: Company Overview - Zevra Therapeutics focuses on developing therapies for rare diseases, aiming to create transformational treatments for conditions with limited or no options [5]. - The company employs unique, data-driven strategies to overcome challenges in drug development and make new therapies available to the rare disease community [5].